Second generation meningococcal OMP-LPS vaccines.
作者信息
Poolman J T, van der Ley P A, Wiertz E J, Hoogerhout P
机构信息
Unit for Bacterial Vaccine Development and Pathogenesis Research, National Institute for Public Health and Environmental Protection, Bilthoven, The Netherlands.
出版信息
NIPH Ann. 1991 Dec;14(2):233-41.
PMID:1725922
Abstract
摘要
相似文献
1
Second generation meningococcal OMP-LPS vaccines.
NIPH Ann. 1991 Dec;14(2):233-41.
2
Development of a second generation group B meningococcal vaccine.第二代B群脑膜炎球菌疫苗的研发
NIPH Ann. 1991 Dec;14(2):225-30; discussion 230-1.
3
Development of a meningococcal vaccine.
Infect Agents Dis. 1995 Mar;4(1):13-28.
4
Polysaccharides and membrane vaccines.多糖疫苗和膜疫苗。
Adv Biotechnol Processes. 1990;13:57-86.
5
Immunoblotting studies of vaccinee and patient sera from a Norwegian serogroup B meningococcal vaccination trial.对来自挪威B群脑膜炎球菌疫苗接种试验的接种者和患者血清进行的免疫印迹研究。
NIPH Ann. 1991 Dec;14(2):183-4; discussion 185-6.
6
The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.B群脑膜炎奈瑟菌的荚膜多糖作为疫苗开发的载体。
Contrib Microbiol Immunol. 1989;10:151-65.
7
Meningococcal serogroup B vaccine protection trial and follow-up studies in Chile. The Chilean National Committee for Meningococcal Disease.智利B群脑膜炎球菌疫苗保护试验及随访研究。智利国家脑膜炎球菌病委员会。
NIPH Ann. 1991 Dec;14(2):211-2; discussion 213.
8
Adverse events following vaccine or placebo injection in an efficacy trial of an outer membrane vesicle vaccine against group B meningococcal disease in Norwegian secondary schools 1988-1991.1988 - 1991年在挪威中学进行的一项针对B群脑膜炎球菌病的外膜囊泡疫苗效力试验中，接种疫苗或安慰剂后的不良事件。
NIPH Ann. 1991 Dec;14(2):133-4; discussion 136-7.
9
The meningococcal serogroup B vaccine protection trial in Norway 1988-1991: trial surveillance by an independent group.1988 - 1991年挪威B群脑膜炎球菌疫苗保护试验：由独立小组进行的试验监测
NIPH Ann. 1991 Dec;14(2):135-6; discussion 136-7.
引用本文的文献
1
Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model.在小鼠鼻腔攻击模型中评估重组脂化P2086蛋白作为B群脑膜炎奈瑟菌疫苗候选物的效果。
Infect Immun. 2005 Oct;73(10):6838-45. doi: 10.1128/IAI.73.10.6838-6845.2005.
2
Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design.脑膜炎球菌外膜蛋白PorA的抗原多样性对流行病学分析和疫苗设计具有重要意义。
Clin Diagn Lab Immunol. 1996 Jul;3(4):444-50. doi: 10.1128/cdli.3.4.444-450.1996.
3
Immune responses in humans and animals to meningococcal transferrin-binding proteins: implications for vaccine design.人类和动物对脑膜炎球菌转铁蛋白结合蛋白的免疫反应：对疫苗设计的启示。
Infect Immun. 1994 Jul;62(7):2984-90. doi: 10.1128/iai.62.7.2984-2990.1994.
4
Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.三剂挪威B群脑膜炎球菌疫苗接种后人体对脑膜炎球菌外膜抗原的抗体反应。
Infect Immun. 1995 Dec;63(12):4642-52. doi: 10.1128/iai.63.12.4642-4652.1995.
Zotero 插件